Jasper Therapeutics Inc (JSPR)
22.98
+0.14
(+0.59%)
USD |
NASDAQ |
May 17, 16:00
22.98
0.00 (0.00%)
After-Hours: 20:00
Jasper Therapeutics Cash from Operations (TTM): -57.47M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -57.47M |
| December 31, 2023 | -52.07M |
| September 30, 2023 | -48.23M |
| June 30, 2023 | -45.90M |
| March 31, 2023 | -41.98M |
| Date | Value |
|---|---|
| December 31, 2022 | -45.86M |
| September 30, 2022 | -47.80M |
| June 30, 2022 | -45.26M |
| March 31, 2022 | -41.70M |
| December 31, 2021 | -33.68M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-57.47M
Minimum
Mar 2024
-33.68M
Maximum
Dec 2021
-45.99M
Average
-45.88M
Median
Cash from Operations (TTM) Benchmarks
| NovaBay Pharmaceuticals Inc | -4.516M |
| Palatin Technologies Inc | -33.74M |
| iBio Inc | -18.89M |
| Theriva Biologics Inc | -18.27M |
| Oragenics Inc | -7.291M |